Diabetic Retinopathy Intelligent Screening Technology integrated
DRISTi is a patented and TGA certified medical device for the early detection of Diabetic Retinopathy.
Diabetic Retinopathy is a complication of the eye caused by poorly managed diabetes mellitus – Type 1 or 2 or gestational diabetes.
The condition is caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina).
Initially Diabetic Retinopathy may cause mild to no symptoms, but if left untreated, it can lead to blindness.
Diabetes affects approximately one million Australian adults. The number is expected to double by the year 2025.
On average one in three people with diabetes will develop some form of diabetic eye disease.
Diabetic Retinopathy affects over one third of all people with diabetes and is the leading cause of vision loss. Globally the prevalence of diabetes is increasing rapidly. Since Diabetic Retinopathy is a progressive disease, early stage detection and treatment can save the patient from losing sight. Due to the alarming increase of Diabetic Retinopathy the screening for Diabetic Retinopathy every 6 months becomes important to check progression of Diabetic Retinopathy.
The AI Product Diabetic Retinopathy Screening System is a novel and cost effective screening tool for identifying presence of Diabetic Retinopathy with a Sensitivity and Specificity above 90.
The AI product not only identifies the presence of Diabetic Retinopathy during screening, it also segments the region for lesions or abnormalities present in fundus images, which helps the doctors to accurately diagnose the presence or absence of Diabetic Retinopathy.
The prevalence of Diabetic Retinopathy is increasing worldwide,due to these increasing numbers screening for early detection of Diabetic Retinopathy and have regularly screening for every 6 months to check the progression of Diabetic Retinopathy becomes important.
The AI product is used to grade the quality of retina image captured by Fundus camera during the Diabetic Retinopathy screening, which the Doctors view for further diagnosis.
It is important for doctors to view gradable fundus images to accurately diagnose the presence or absence of Diabetic Retinopathy versus viewing non gradable fundus images which might increase the chances of misdiagnosis due to poor quality image.
Case Studies of AI in action – The First Mile of Healthcare delivery
Case Study 1: Improving customer conversion rates
Case Study 2: AI powered screening in public healthcare
Case Study 3: Bridging the patient- specialist gap
Case Study 4: AI Powered Social Missions
How It Works
Towards Human Level Accurate Deep Learning System for Diabetic Retinopathy Screening.
Diabetic Retinopathy Screening using Deep Learning Technology.
The Deep Learning Computer model in reading Diabetic Retinopathy & Normal Images.